What price did Alexander A. Fitzpatrick receive per share in the SPRY stock sale?

Alexander A. Fitzpatrick’s reported sale of ARS Pharmaceuticals common stock was executed at a price of $10.00 per share. The transaction involved 3,355 shares in an open-market sale, as disclosed in the Form 4 insider trading report.

ARS Pharma CLO sells 3,355 SPRY shares at $10

ARS Pharmaceuticals Chief Legal Officer Alexander A. Fitzpatrick reported an open-market sale of 3,355 shares of common stock at $10.00 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ARS Pharmaceuticals Chief Legal Officer Alexander A. Fitzpatrick reported an open-market sale of 3,355 shares of common stock at $10.00 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025 and leaves him holding 90,910 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 3,355 shares

Net Sell 1 txn

Insider Fitzpatrick Alexander A

Role Chief Legal Officer

Sold 3,355 shs ($34K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,355	$10.00	$34K

Holdings After Transaction: Common Stock — 90,910 shares (Direct)

Footnotes (2)

F1. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2. Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025.

Key Figures

Shares sold: 3,355 shares Sale price: $10.00 per share Shares held after transaction: 90,910 shares +2 more

5 metrics

Shares sold 3,355 shares Open-market sale of common stock

Sale price $10.00 per share Reported transaction price

Shares held after transaction 90,910 shares Direct ownership following sale

ESPP acquisition June 2025 2,907 shares Acquired under 2020 ESPP on June 30, 2025

ESPP acquisition December 2025 1,745 shares Acquired under 2020 ESPP on December 31, 2025

Key Terms

Rule 10b5-1 trading plan, Employee Stock Purchase Plan, Common Stock

3 terms

Rule 10b5-1 trading plan financial

"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Purchase Plan financial

"Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARS Pharmaceuticals (SPRY) report for Alexander A. Fitzpatrick?

ARS Pharmaceuticals reported that Chief Legal Officer Alexander A. Fitzpatrick sold 3,355 shares of common stock in an open-market transaction at $10.00 per share. After this sale, he directly holds 90,910 shares of ARS Pharmaceuticals common stock.

Was the SPRY insider stock sale by Alexander A. Fitzpatrick pre-planned under Rule 10b5-1?

Yes. The 3,355-share sale by Alexander A. Fitzpatrick was made pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. Such plans allow insiders to schedule trades in advance, helping separate transactions from day-to-day market timing decisions.

How many ARS Pharmaceuticals (SPRY) shares does Alexander A. Fitzpatrick hold after the reported sale?

Following the reported transaction, Alexander A. Fitzpatrick directly owns 90,910 shares of ARS Pharmaceuticals common stock. This figure reflects his position after selling 3,355 shares at $10.00 per share in the open market, according to the Form 4 filing.

Does the ARS Pharmaceuticals Form 4 mention employee stock purchase plan (ESPP) shares for SPRY?

Yes. The filing notes that Fitzpatrick’s holdings include 2,907 shares acquired under the 2020 Employee Stock Purchase Plan on June 30, 2025 and 1,745 shares acquired under the same ESPP on December 31, 2025, both contributing to his current ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/12/2026 - 08:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzpatrick Alexander A

(Last)

(First)

(Middle)

C/O ARS PHARMACEUTICALS, INC.

11682 EL CAMINO REAL, SUITE 300

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARS Pharmaceuticals, Inc. [ SPRY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/12/2026		S⁽¹⁾		3,355	D	$10	90,910⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

2. Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025.

	/s/ Kathleen Scott, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR